United Kingdom Pharmacovigilance and Drug Safety Software Market Size & Outlook, 2025-2033
United Kingdom Pharmacovigilance and Drug Safety Software Market Insights
- Reed Intelligence analysis indicates that the United Kingdom Pharmacovigilance and Drug Safety Software Market size, valued at USD 8.31 Million in 2024, is expected to expand to USD 15.5 Million by 2033.
- The United Kingdom market is forecasted to expand at a CAGR of 7.05% spanning 2026–2033.
- Case data collection and management held the leading position among By Functionality segments in 2024, based on market size.
- Adverse event reporting and analysis is projected to post the fastest growth rate, sustaining its position as the most attractive By Functionality segment during the forecast horizon.
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- In 2024, United Kingdom represented 4.04% of the overall global Pharmacovigilance and Drug Safety Software Market size.
- United States is projected to lead the global Pharmacovigilance and Drug Safety Software Market size by 2033.
- Across Europe, Germany is anticipated to hold the dominant position in market size by 2033.
- Germany is forecasted to expand at the fastest pace in Europe, attaining USD 19.25 Million by 2033.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2024 |
| Study Period | 2021-2033 |
| Historical Period | 2021-2023 |
| Forecast Period | 2025-2033 |
| Market Size In 2024 | USD 8.31 Million |
| Market Size In 2033 | USD 15.5 Million |
| Largest segment | Case data collection and management |
| Units | Revenue in USD Million |
| CAGR | 7.05% (2025-2033) |
| Segmnetation Covered | |
| By Functionality |
|
| By Delivery Mode |
|
| By End Use |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
United Kingdom Pharmacovigilance and Drug Safety Software Market By Functionality 2025-2033 (USD Million)
| By Functionality | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Case data collection and management | XX.x | XX.x | XX.x | 3.75 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Adverse event reporting and analysis | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Signal detection and other safety risk assessment | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
United Kingdom Pharmacovigilance and Drug Safety Software Market By Delivery Mode 2025-2033 (USD Million)
| By Delivery Mode | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| On Premise | XX.x | XX.x | XX.x | 4.83 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| On Demand | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
United Kingdom Pharmacovigilance and Drug Safety Software Market By End Use 2025-2033 (USD Million)
| By End Use | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Healthcare Companies | XX.x | XX.x | XX.x | 4.43 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| CROs/BPOs/PV service providers | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Others | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
